Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas

References

1. 1.↵
   2. Friedman HS,
   3. Prados MD,
   4. Wen PY, et al

   . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733–40 doi:10.1200/JCO.2008.19.8721 pmid:19720927

   Abstract/FREE Full Text
2. 2.↵
   2. Chamberlain MC

   . Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 2011;5:117–29 doi:10.4137/CMO.S7232 pmid:21603247

   CrossRefPubMed
3. 3.↵
   2. Le Rhun E,
   3. Rhun EL,
   4. Taillibert S, et al

   . The future of high-grade glioma: where we are and where are we going. Surg Neurol Int 2015;6(suppl 1):S9–S44 doi:10.4103/2152-7806.153100 pmid:25722939

   CrossRefPubMed
4. 4.↵
   2. Khasraw M,
   3. Ameratunga MS,
   4. Grant R, et al

   . Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev 2014;9:CD008218 doi:10.1002/14651858.CD008218.pub3 pmid:25242542

   CrossRefPubMed
5. 5.↵
   2. Wen PY,
   3. Macdonald DR,
   4. Reardon DA, et al

   . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

   Abstract/FREE Full Text
6. 6.↵
   2. Pope WB,
   3. Young JR,
   4. Ellingson BM

   . Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 2011;11:336–44 doi:10.1007/s11910-011-0179-x pmid:21234719

   CrossRefPubMed
7. 7.↵
   2. Hygino da Cruz LC Jr.,
   3. Rodriguez I,
   4. Domingues RC, et al

   . Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011;32:1978–85 doi:10.3174/ajnr.A2397 pmid:21393407

   Abstract/FREE Full Text
8. 8.↵
   2. Boxerman JL,
   3. Zhang Z,
   4. Safriel Y, et al

   . Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro Oncol 2013;15:945–54 doi:10.1093/neuonc/not049 pmid:23788270

   Abstract/FREE Full Text
9. 9.↵
   2. Prados M,
   3. Cloughesy T,
   4. Samant M, et al

   . Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:143–51 doi:10.1093/neuonc/noq151 pmid:21084434

   Abstract/FREE Full Text
10. 10.↵
    2. Ellingson BM,
    3. Cloughesy TF,
    4. Lai A, et al

    . Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:401–09 doi:10.1093/neuonc/noq206 pmid:21324937

    Abstract/FREE Full Text
11. 11.↵
    2. Huang RY,
    3. Rahman R,
    4. Hamdan A, et al

    . Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer 2013;119:3479–88 doi:10.1002/cncr.28210 pmid:23821555

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Ellingson BM,
    3. Kim HJ,
    4. Woodworth DC, et al

    . Recurrent glioblastoma treated with bevacizumab: contrast enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 2014;271:200–10 doi:10.1148/radiol.13131305 pmid:24475840

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Schmainda KM,
    3. Prah M,
    4. Connelly J, et al

    . Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol 2014;16:880–88 doi:10.1093/neuonc/not216 pmid:24431219

    Abstract/FREE Full Text
14. 14.↵
    2. Aquino D,
    3. Di Stefano AL,
    4. Scotti A, et al

    . Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. PLoS One 2014;9:e90535 doi:10.1371/journal.pone.0090535 pmid:24675671

    CrossRefPubMed
15. 15.↵
    2. Sawlani RN,
    3. Raizer J,
    4. Horowitz SW, et al

    . Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging: pilot study. Radiology 2010;255:622–28 doi:10.1148/radiol.10091341 pmid:20413772

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Ellingson BM,
    3. Sahebjam S,
    4. Kim HJ, et al

    . Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. AJNR Am J Neuroradiol 2014;35:673–79 doi:10.3174/ajnr.A3748 pmid:24136647

    Abstract/FREE Full Text
17. 17.↵
    2. Zach L,
    3. Guez D,
    4. Last D, et al

    . Delayed contrast extravasation MRI: a new paradigm in neuro-oncology. Neuro Oncol 2015;17:457–65 doi:10.1093/neuonc/nou230 pmid:25452395

    Abstract/FREE Full Text
18. 18.↵
    2. Zach L,
    3. Guez D,
    4. Last D, et al

    . Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors. PLoS One 2012;7:e52008 doi:10.1371/journal.pone.0052008 pmid:23251672

    CrossRefPubMed
19. 19.↵
    2. Taal W,
    3. Oosterkamp HM,
    4. Walenkamp AM, et al

    . Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943–53 doi:10.1016/S1470-2045(14)70314-6 pmid:25035291

    CrossRefPubMedWeb of Science